What is the mechanism of action of ruxolitinib myelofibrosis?
•
2 min read
Affecting thousands, myelofibrosis is a serious blood cancer characterized by an overactive Janus kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) signaling pathway. Ruxolitinib is a targeted therapy that addresses this core issue, providing significant symptom relief and improving patient outcomes. The mechanism of action of ruxolitinib in myelofibrosis centers on potent inhibition of key Janus kinases, altering disease progression.
